ARS Pharmaceuticals Inc (NASDAQ:SPRY)’s traded shares stood at 0.73 million during the last session, with the company’s beta value hitting 0.87. At the close of trading, the stock’s price was $14.02, to imply an increase of 0.14% or $0.02 in intraday trading. The SPRY share’s 52-week high remains $18.51, putting it -32.03% down since that peak but still an impressive 64.27% since price per share fell to its 52-week low of $5.01. The company has a valuation of $1.36B, with an average of 0.91 million shares in intraday trading volume over the past 10 days and average of 1.06 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for ARS Pharmaceuticals Inc (SPRY), translating to a mean rating of 1.00. Of 4 analyst(s) looking at the stock, 0 analyst(s) give SPRY a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.11.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ARS Pharmaceuticals Inc (NASDAQ:SPRY) trade information
After registering a 0.14% upside in the last session, ARS Pharmaceuticals Inc (SPRY) has traded red over the past five days. The 5-day price performance for the stock is -3.38%, and -10.81% over 30 days. With these gigs, the year-to-date price performance is 155.84%. Short interest in ARS Pharmaceuticals Inc (NASDAQ:SPRY) saw shorts transact 13.85 million shares and set a 10.98 days time to cover.
The extremes give us $22 and $30 for target low and target high price respectively. As such, SPRY has been trading -113.98% off suggested target high and -56.92% from its likely low.
ARS Pharmaceuticals Inc (SPRY) estimates and forecasts
Looking at statistics comparing ARS Pharmaceuticals Inc share performance against respective industry, we note that the company has underperformed competitors. ARS Pharmaceuticals Inc (SPRY) shares are 59.14% up over the last 6 months, with its year-to-date growth rate lower than industry average at -1.75% against 16.60%. The rating firms project that company’s revenue will grow 65,436.67% compared to the previous financial year.
Revenue forecast for the current quarter as set by 4 analysts is 17.08M. Meanwhile, for the current quarter, a total of 3 analyst(s) estimate revenue growth to 17.03M.
SPRY Dividends
ARS Pharmaceuticals Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
ARS Pharmaceuticals Inc (NASDAQ:SPRY)’s Major holders
ARS Pharmaceuticals Inc insiders hold 23.30% of total outstanding shares, with institutional holders owning 68.14% of the shares at 88.83% float percentage. In total, 68.14% institutions holds shares in the company, led by DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C). As of 2024-06-30, the company held over 11.08 million shares (or 11.4409% of shares), all amounting to roughly $94.27 million.
The next major institution holding the largest number of shares is RA CAPITAL MANAGEMENT, L.P. with 10.86 million shares, or about 11.2168% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $92.43 million.
